Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $6.95, for a total value of $34,750.00. Following the completion of the sale, the chief technology officer directly owned 187,171 shares of the company’s stock, valued at $1,300,838.45. The trade was a 2.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total value of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total value of $38,261.44.

SOPHiA GENETICS Trading Up 6.2%

SOPHiA GENETICS stock opened at $6.69 on Friday. The stock has a 50-day moving average of $5.57 and a two-hundred day moving average of $5.13. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.90 and a current ratio of 2.69. SOPHiA GENETICS SA has a one year low of $2.96 and a one year high of $7.21. The stock has a market cap of $561.22 million, a PE ratio of -5.82 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. On average, research analysts anticipate that SOPHiA GENETICS SA will post -0.58 EPS for the current fiscal year.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, implying 22%–24% year-over-year growth and exceeding the roughly $93.4 million consensus estimate. Management continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook article
• Positive Sentiment: The company entered a multi-year global collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The partnership could expand SOPH’s commercial reach and provide longer-term growth opportunities. SOPHiA GENETICS AstraZeneca partnership article
• Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target from $12 to $14. BTIG Research also maintained a Buy rating and lifted its target from $8 to $9, signaling improved confidence in the company’s growth prospects.
• Positive Sentiment: Second-quarter revenue rose 27% year over year to $23.31 million, surpassing the $21.72 million consensus estimate. The adjusted EBITDA loss also improved by 27% to $8.8 million.
• Neutral Sentiment: HC Wainwright reduced its FY2029 EPS estimate to $0.31 from $0.34 but increased its FY2030 forecast to $0.72 from $0.69. The firm’s $14 target and Buy rating were unchanged, suggesting near-term forecast pressure but stronger longer-term expectations.
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu sold a combined 35,000 shares for approximately $242,350 under pre-arranged Rule 10b5-1 plans. Their remaining ownership stakes declined only modestly, reducing the significance of the sales as a bearish signal.
• Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, worse than the expected $0.21 loss. The company remains deeply unprofitable, with a negative net margin and analysts forecasting a full-year loss of approximately $0.58 per share.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. HC Wainwright upped their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, BTIG Research upped their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, SOPHiA GENETICS has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after buying an additional 5,432,871 shares during the period. Akre Capital Management LLC boosted its position in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Principal Financial Group Inc. boosted its position in SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Archon Capital Management LLC grew its stake in shares of SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares during the period. Finally, Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 1st quarter valued at approximately $2,157,000. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.